A Phase 1, Two-Way Crossover Study to Assess the Pharmacokinetics and Safety of a Single Dose of AG-221 in Healthy Male Subjects When Administered Under Fed and Fasted Conditions

Trial Profile

A Phase 1, Two-Way Crossover Study to Assess the Pharmacokinetics and Safety of a Single Dose of AG-221 in Healthy Male Subjects When Administered Under Fed and Fasted Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2015

At a glance

  • Drugs Enasidenib (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 29 Sep 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 03 Nov 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 03 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top